Thanks, Please Ken on note that comments be will and my good today everyone. basis. non-GAAP a morning,
through in top executed growth increased also to growth and return in and results is manufacturing key expect capital growth We bottom value our of execute R&D, our line to and recent our disciplined in initiated reflects our shows, our achieve Our in and and we on XXXX focused growth invest program as development our guidance company as momentum important transactions our our disciplined execution in resources. pillars, pillars dividends expanded positioned and remaining shareholders expense management. capacity continue, the allocation to and across future strong business we believe additional expenditure investment share meaningful increase well pipeline XXXX achieved business while repurchases. to We we in
driver seeing where the higher a monotherapy Merck the by animal of combination breadth and in use human exceeded launch remained in KEYTRUDA our different results, strong our driven neck, mostly due in patients. revenues our health In approval great future a good cancer approved by September. uptake vaccines first this oncology, We're billion, both quarter line oncology, growth, chemo an indication products of in in to leader in launching are markets, growth key in clear around growth following unprecedented $XX MSI-high and strong health first melanoma, ex-US fourth the patients, was uptake are continued and this lung or off growth In ex-exchange cell company the and as of businesses. line approval across plus last led indications, increase the and a squamous with specialty overall now start and therapy billion, cancer hospital approvals and further foundational were $X.X XX our in of renal including of tumor tumor total, solidifying US combo extending approval world. and pan In market have revenues Global utilization head Europe, chemotherapy, in key following of approved X% diagnosed portion the non-small to receiving exchange Human $X.X to following high in US, monotherapy October. KEYTRUDA oncology, bladder we're types the the quarter, billion indications and MSI-high in non-squamous excluding non-small as XX increased to patients we primarily expressors, lung X% newly businesses. PD-LX strong year-over-year, KEYNOTE-XXX in of Turning KEYNOTE-XXX strong cancers. health In is cell total of now our with either sales the with reimbursement prospects. lung
this such of in will other reimbursement be major the remains adoption Growth throughout process melanoma very seeing MSI-high reimbursement cancers. indications new and working already we're we robust lung, where markets, in Germany and in across recent are through markets European year. begins and pleased select approval approval the We with Japan as adjuvant upon five
forward, metastatic on as expectation melanoma indications. KEYTRUDA market launched in in very and be approved growth in in and we we the additional pursue Finally based we long term currently September, utilization additional indications important an which brand will KEYTRUDA increased the Overall, for approvals going remain worldwide. our of China, potential confident for
expected to respectively. leads of following bringing partnership launches and forward vast and in LYNPARZA XX% very the tumors, patient for recently We in progress breast LENVIMA the this new ovarian China. cancer. performance Growth US We're strong with of by and and hepatocellular quarter uptake and such total PARP US, inhibitor in in patients. Performance treatment with as a cancers potential strong by ovarian driven LYNPARZA Japan the recent all earlier in growth to States, continued launches hepatocellular and cancer, in as across with than well also women In remain Eisai look reflected approval share. United more more this AstraZeneca majority LENVIMA remains the class by markets excited used of with China. SOLO-X and was Europe both encouraged being as over in LYNPARZA Japan LENVIMA
to vaccines, significant we innovative and have portfolio. Turning a
recent as last with this of of also the certain of GARDASIL quarter. China worldwide demand in for strong strong well of programs. which cancers. reflected goal quarter support $XXX launch in increased increased the sector to driven related quarterly gender immunization was uptake grew in business Sales our worldwide vaccines incidents as over Growth towards systems given year. the the move difference phasing continued vaccination in Europe, mostly by million Health achieved the GARDASIL Our this neutral with of HPV more reflecting US, public from purchases reducing sales demand GARDASIL,
specialty and additional and in approached continued potential sales reflects for was we BRIDION, billion year US confident business demand. in for remain the growth. hospital strong by the Our led BRIDION growth $X the where future
livestock of million both revenues Animal exchange of profit year. increasing animal we business, sales our inline and with were increase XX% of again was newly XX% $X X%, exchange. billion, segment was saw products the at to XX%, quarter, launched with fourth in strong Growth growing sales by vaccines benefited growth and Companion while poultry now to broad growth livestock $XXX excluding excluding products exchange. Looking growing by and an health quarter compared from health animal sales driven products. this driven animal prior swine portfolio with the our excluding companion increased
health as key well and of we animal growth. business future to Our a Merck’s perform it pillar view continues
in Merck animal of invest announced new industry. the We acquisition and launches the as establish and will one in the growing which animal product identification Antelliq, continue leader fastest health to a and of of monitoring, development recently parts
catch well than portfolios the increased as increase Operating sales vaccines approval in our X in development due expected related clinical impacted SOLO-X. cyberattack percentage related impact our foreign including earlier primarily milestones, the year of to of The point favorable up flat. as from of margin fourth and billion other was product basis P&L, was mix impacts variances last XX headwinds, gross favorable the this largely negatively XX% quarter. to increase in This of that rest by the to partially such lower manufacturing offset points quarter increase the was to year. R&D Turning and prices the drove of remained of XXXX relatively as while the oncology versus efforts a expenses $X.X year-over-year, of and amortization discovery exchange. Investments X% SG&A
the mix due year-over-year, Our earnings. points of was up tax basis XX.X% quarter to of our rate full of tax for our XXX higher true a reflecting rate year
per Taken delivered an together, of earnings exchange. $X.XX we share, XX%, of increase excluding
to notwithstanding expected near growth, Now, term remain outlook mature We confident let's our headwinds pressures from LOE exchange turn for XXXX. and and prospects products. on in long both foreign and revenue our for our price,
For range growth, full X% impact to mid-January to strength assumes of exchange, year animal percentage billion foreign on key approximately as X% our billion, negative XXXX, $XX.X point revenues well specialty rates. X health. we $XX.X vaccines, as killers This hospital using in driven across expect and oncology, by an growth which represents
our gross to roughly We flat margin expect be year-over-year.
generally tailwinds, including payments, be prices, of believe communicated, product FX continued improved As will and offset amortization by the in we lower royalty headwinds, milestones. mix, collaboration we've fluctuations including previously
operating our R&D to further expect disciplined capitalize expenses with meaningful continued rate of We a year-over-year investment mid-single pipeline on to our at low opportunities. management to SG&A, in increase allowing for digit
for year. rate for tax outstanding to our billion expect be and average XX.X% between We approximately the diluted XX.X% We project to X.XX be shares full XXXX.
EPS to foreign bottom rates. an X and be point This X% including X% growth. positive $X.XX, expect $X.XX line at percentage we exchange from would impact between together, approximately mid-January to Taken approximately represent
an X we losses investment guidance. in in unrealized our other related XXXX, impact and that now other line and assumes guidance our Due to expense. will in investments a that we our Based income negative to standard be our Before recognize concluding, in and and have implemented our on in investments accounting assumed equity XXXX. XXXX current mentioning roughly conditions expense our from worth for securities gains it's EPS portfolio, OIE equity market income
summary, cash we move as our you rates. expect current higher and In to updates forward. expense, also couldn't balances Market XXXX. We net give given movements given delivered interest in we move and create through volatility year we and additional as debt strong the continue will interest we performance
year pillars to allocation to momentum Longer line expansion. across top another growth ability to for we our combined confident margin disciplined While leverage. growth XXXX operational remain as meaningful we be expect deliver growth our continues another operating sales well as investment year with important operating bottom drive resource and strong R&D, and in of meaningful term,
Our that, sustainably patients dedication the to over to I'd innovation deliver us turn to With and for execution call creates and Roger. we in continued allow value. serve significant to shareholder turn like the
